AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 91 min read$COSM

Cosmos Health reports record ~$54.3M nine-month revenue; Q3 ~$17.4M, reaffirms >$90M 2026 outlook

Cosmos Health reported preliminary nine-month 2026 revenue of $54.3M, up 19% YoY, with Q3 revenue at $17.4M, a record. The company reaffirmed its full-year 2026 revenue outlook of over $90M, citing growth across all segments and record production and distribution milestones.

Original reporting
tradingview.com
Published Oct 9, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cosmos Health reports record ~$54.3M nine-month revenue; Q3 ~$17.4M, reaffirms >$90M 2026 outlook — source image
Source · tradingview.com
Decision brief

The 30-second read

$COSMBullishMed
01

Why it matters

The key tradable elements are the record Q3 revenue level and the reaffirmation that full-year 2026 revenue will surpass $90M, with Q4 expected to be the strongest quarter.

02

Market read

This is a company-specific revenue update with reaffirmed guidance, which can shift expectations for Q4 and the 2026 revenue trajectory.

03

What to watch

The article highlights revenue and operational pipeline/volume milestones but does not discuss profitability, working capital, or customer concentration, which can dominate valuation follow-through.

Relevance 7/10Novelty 7/10Timing: after-hours/late-day following the Oct. 9, 2026 8-K filing

Background

Cosmos Health filed an Oct. 9, 2026 8-K with preliminary, unaudited revenue for nine months ended Sept. 30, 2026 and provided business highlights.

Company-level read

Ticker impact

$COSMBullishMedium confidence
Context

Cosmos Health reported preliminary nine-month revenue of about $54.3M and reaffirmed full-year 2026 revenue to surpass $90M.

Expected impact

Likely upward bias as traders price in stronger-than-expected run-rate and confidence in the 2026 revenue target.

Evidence & confidence

The article provides fresh preliminary revenue figures plus a reiterated full-year guidance level, which can drive near-term sentiment and positioning.

Market effects

Sector

Supports sentiment for small-cap contract manufacturing and branded pharma distribution names, but impact is likely limited beyond the issuer.

Regional

No clear regional spillover indicated; story is company-specific.

Global

No direct global macro or cross-border catalyst described.

Counterpoint

What could challenge this read

Preliminary, unaudited revenue and a reaffirmed outlook may be less informative than audited results, so the market may discount the numbers if margins or cash flow are not addressed.

Key entities

  • public_company
    Cosmos Health Inc.

    Reported preliminary nine-month and Q3 2026 revenue and reaffirmed full-year 2026 revenue outlook above $90M.

Read at source← All news

Related articles

OCT 9
$COSMMedAI 8/10

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and…

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million ● Record nine-month revenue of approximately $54.3 million — up 19%

SEC EDGAR 8-K4 min
AUG 20
$COSMMed

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities…

Cosmos Health Inc. (COSM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway · Highest Q2 and H1 revenue in Com

SEC EDGAR 8-K2 min
JUL 13
$COSMMed

Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece

Cosmos Health (NASDAQ:COSM) said it signed a five-year agreement with Libytec to commercialize DIABIT-IS X (sitagliptin) in Greece. Cosmos, via Cana, will supply the drug, while Libytec will distribute and promote it to physicians and pharmacies. The company expects the deal to support revenue and cash-flow visibility, citing Greece’s national reimbursement system.

manilatimes.net4 min